Avance Clinical Sponsors Prestigious Citeline Awards 2025 To Recognize Innovative Biotechnology Companies
ADELAIDE, Australia and BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning, global CRO for biotechs, is proud to announce its sponsorship of the Citeline Awards 2025, to be held in Boston tomorrow, May 8, 2025. Recognized as a premier celebration of innovation and excellence in clinical R&D, the Citeline Awards honor the most significant achievements across the global biopharma industry.
Now in its ninth year, the Citeline Awards attract leading biotechs, pharma innovators, and clinical research organizations. This year's categories include Excellence in Rare Disease Drug Development, Most Successful Early Phase Research (Preclinical & Phase I), and Clinical Research Team of the Year – Biotech, highlighting the leaders and organizations driving advancements in the sector.
Avance Clinical's sponsorship reflects the company's commitment to supporting biotechs from early to late phase development across Australia, New Zealand, Asia, North America and Europe. With its proven GlobalReady program and agile biotech-focused model, Avance Clinical enables emerging biopharma companies to achieve accelerated development timelines, backed by world-class data accepted by global regulatory authorities including the FDA and EMA.
Yvonne Lungershausen, CEO of Avance Clinical, said: 'As a company dedicated to partnering with innovative biotechs globally, we are honored to sponsor the Citeline Awards. These awards celebrate the spirit of innovation and excellence that drives our industry forward. We congratulate all the finalists for their extraordinary achievements and their commitment to advancing therapies that improve patient outcomes.'
The Citeline Awards 2025 ceremony will take place at the Hyatt Regency Boston, in the Downtown Boston Theater District, bringing together top industry leaders, investors, and biotech pioneers for an evening of recognition and networking.
For more information about the Citeline Awards 2025 and to view the full list of finalists and categories, visit Citeline Awards .
About Avance Clinical
Avance Clinical is a leading Contract Research Organization (CRO) offering biotech companies faster, more flexible, and higher-quality clinical trial services. As the largest premium full-service CRO headquartered in Australia, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe for international biotechs. With 30 years of experience and expertise spanning over more than 250 indications, the company provides comprehensive clinical research services from early to late-phase trials.
Find out more:
Media Enquiries: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Bitcoin Solaris Presale Surges Past $3.8M as Final $6 Phase Nears Close
By GlobeNewswire Published on June 8, 2025, 16:11 IST TALLINN, Estonia, June 08, 2025 (GLOBE NEWSWIRE) — The crypto community is buzzing as Bitcoin Solaris (BTC-S) crosses a major milestone, raising $3.8 million in its ongoing presale. With over 11,000 participants already onboard and the token price still at just $6, this marks one of the most rapid early-stage raises of 2025. Built with a clear focus on speed, decentralization, and developer-ready infrastructure, Bitcoin Solaris is more than just another token—it's a full-stack blockchain ecosystem gearing up for mainnet launch. The current phase of the presale is expected to end within days, ahead of the next price jump to $7. Why Bitcoin Solaris Is Outpacing the Crypto Pack Bitcoin Solaris was built to take the best of each and leave the problems behind. Here's how it does that: Combines Proof-of-Work and Delegated Proof-of-Stake for a dual-consensus model. Runs up to 100,000 TPS on the Solaris Layer, with 2-second finality. Secures its Base Layer with SHA-256, keeping it compatible with existing mining rigs. Includes 21 rotating validators, ensuring decentralization with performance. Why Everyone Is Talking About It From top Telegram groups to influencer channels, the buzz around Bitcoin Solaris is only growing. The detailed breakdown by Ben Crypto highlights why this project stands out in a sea of overpromises. With real use cases, deep audits, and a scalable structure, the hype isn't artificial—it's earned. What makes this even more incredible? The presale isn't even over yet. Current phase: 6 (last day) Current price: $6 Next phase: $7 Launch price: $20 Potential return: 1,900% Already raised: $3.8 million This is being hailed as one of the shortest and most explosive presales in recent memory, and the countdown has officially begun. Core Features That Power the Frenzy At the heart of Bitcoin Solaris is one idea: speed without compromise. Let's break down why it's different: Hybrid PoW/DPoS Consensus: Maintains decentralization while enabling speed. Validator Rotation: Every 24 hours, keeping the system agile and secure. Energy Efficiency: Uses 99.95% less power than Bitcoin. Cross-Chain Bridges: Built-in support for interoperability with Solana and others. Rust-Based Smart Contracts: Initially leveraging Solana tools for dApps and DeFi expansion. Audited Infrastructure: Smart contracts have been fully reviewed by Cyberscope and Freshcoins for trust and security. This Is How Bitcoin Solaris Will Make People Rich Wealth isn't made by buying late. It's built by spotting what's early—but solid. Bitcoin Solaris isn't a copycat. It's a new layer of infrastructure designed to generate value for real participants. The reward distribution model ensures that every piece of the network feeds back into the community: 40% of rewards go to miners 25% go to validators 20% go to stakers 10% funds for long-term development 5% support community initiatives Unlike many coins where wealth consolidates at the top, BTC-S is structured to empower long-term holders, contributors, and those who participate early. Real Vision, Real Roadmap Bitcoin Solaris isn't pitching hope—it's executing a plan. Here's the official roadmap: Bitcoin Solaris Roadmap Summary Phase 1 (Q2–Q4 2025): Token generation, whitepaper, core devs, and presale launch Phase 2 (Q1 2026): Testnet, wallet, bridge integration, architecture optimization Phase 3 (Q2 2026): Final mainnet prep, dev tools, exchange listings Phase 4 (Q3 2026): Mainnet launch, AI-powered app release, governance rollout Phase 5 (Q4 2026): DApp accelerator, Mining Power Marketplace, hardware wallet integration Phase 6 (Q1–Q2 2027): Layer-2 upgrades, DEX, and quantum security Phase 7 (Q3–Q4 2027): Fortune 500 partnerships, institutional tools, Innovation Labs Phase 8 (2028+): AI integration, government collaborations, long-term evolution That's not just a vision board—it's an execution framework already in motion. The Final Surge Is On Bitcoin Solaris isn't just another token looking for attention. It's a serious infrastructure play backed by smart tech, audited code, and a growing army of supporters. With $3.8 million raised and momentum accelerating, this is one of the few presales that feels like more than a hype train. And with the price still sitting at just $6 for a very short time—this might be the final opportunity to ride the wave before it takes off. For more information on Bitcoin Solaris: Website: Telegram: X: Media ContactXander Levine [email protected] Press Kit: Available upon request Disclaimer: This is a paid post and is provided by Bitcoin Solaris . The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Photos accompanying this announcement are available at: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
2 hours ago
- Business Upturn
URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)
NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting Investors have until July 28, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased UroGen securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Cockrell v. UroGen Pharma Ltd., et al. , No. 3:25-cv-06088. Why was UroGen Sued for Securities Fraud? UroGen develops treatments for specialty cancers. The Company's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. One of the Phase 3 trials for UGN-102 is named ENVISION. As alleged, UroGen stated that the ENVISION trial met its primary endpoint and that UroGen had reached 'agreement with the FDA' that the ENVISION trial would support an NDA submission. In truth, the FDA had previously expressed significant concerns to UroGen regarding the ENVISION trial, which lacked a concurrent control arm. The Stock Declines as the Truth is Revealed On May 16, 2025, the FDA published a briefing document stating that it doubted whether the submitted data was sufficient to conclude that UGN-102 was effective. FDA stated that because 'ENVISION lacked a concurrent control arm,' the primary endpoints were 'difficult to interpret' and that UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock declined $2.54 per share, or nearly 26%, from a closing price of $9.85 per share on May 15, 2025, to $7.31 per share on May 16, 2025. Then, on May 21, 2025, the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk profile of UGN-102 was not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock declined $3.37 per share, or nearly 45%, from a closing price of $7.54 per share on May 20, 2025, to $4.17 per share on May 21, 2025. Click here if you suffered losses: What Can You Do? If you invested in UroGen you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
2 hours ago
- Business Upturn
Where the Sea Meets the Skin: Shapellx Unveils Innovative New OceanHug™ Collection Made from Oyster Shells
By GlobeNewswire Published on June 8, 2025, 18:00 IST ORLANDO, Fla., June 08, 2025 (GLOBE NEWSWIRE) — Shapellx , a leading women's shapewear brand, proudly announces the launch of OceanHug™ – a seamless women's wear collection of intimates, outerwear, and shapewear pieces crafted with a first-of-its-kind fabric made from recycled oyster shells. The new sustainable, ocean-inspired collection enhances body contours while delivering the perfect balance of style, comfort, and sustainability. Every year, millions of pounds of oyster shells are discarded, eventually ending up in landfills. Shapellx believes that beauty should never come at the expense of the environment. Every OceanHug™ piece gives new purpose to 33 recycled oyster shells, integrating them into ethically produced, performance-driven fabrics. By turning marine waste into innovation, the collection represents a fresh take on circular fashion by finding a second life for shells that promotes innovation while reducing use of virgin materials. 'As sustainability becomes a top priority for both brands and consumers, Shapellx is proud to lead with innovative materials like oyster protein that combine environmental responsibility with performance-enhancing benefits,' said Shane Shi, Vice President of Shapellx. 'We're committed to delivering more sustainable alternatives without compromising on quality or comfort. OceanHug™ is just the beginning.' The lightweight yet form-fitting OceanHug™ yarn is engineered with breathable, moisture-wicking properties, feeling silky, cool, and comfortable to the touch. The fabric uniquely incorporates collagen peptides and oyster protein fiber, rich in amino acids and trace elements, which can help to nourish the skin and strengthen its barrier. OceanHug™ also offers antibacterial properties, reducing harmful bacteria growth by 2.56%, and is specially processed to be free from irritating chemicals, making it an excellent choice for those with sensitive skin. The new lineup, built with shapewear materials to hug and comfortably embrace the body, comes in soft hues of baby blue, lavender pink, oyster white, and more. The collection includes the following products: OceanHug™ Oyster Reborn Smoothing Bodysuit The delicate lace cup edges expand the coverage around the bust, enhancing the natural bust shape and curve. The waist and abdomen shaping works to tighten and smooth targeted areas for a comfortable, sculpted silhouette. Retails for $54 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, lavender pink and bright red. OceanHug™ Oyster Reborn T-Shirt Bra The OceanHug ™ Seamless Bra is made with high-elasticity yarn and butter-soft fabric for an ultimate comfort experience. The fixed one-piece cup design reduces the risk of cup-shifting for a supportive fit. The back closure is 7cm wide, compared to the traditional 3.5cm, providing better wraparound coverage and enhanced smoothing. Retails for $49 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Brief The briefs feature a mid-waist, hip-hugging seamless design for stable coverage, preventing unwanted digging and squeezing while delivering stretch to fit perfectly on all body types. Made from skin-friendly, soft modal fabric, it provides a gentle and refreshing touch on the skin. Retails for $9 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Cami The V-neckline highlights the collarbone, creating a feminine, flattering look. The built-in 3D molded cups comfortably lift and shape the bust for all-day support. It features an anti-slip grip at the bottom hem to prevent rolling and ensure a smooth, stable fit. The compression fabric around the waist and abdomen smooths the area and provides comfortable shaping. Retails for $49 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, beige and lavender pink. To celebrate both the OceanHug™ launch and World Ocean Day on June 8, Shapellx hosted a pop-up event in NoHo, New York. Attendees were able to experience the OceanHug™ fabric firsthand and received a special gift. Designed to suit your everyday life and standout moments, Shapellx's new OceanHug™ collection is available to purchase at . To learn more about the collection and keep up with the brand, follow along on Instagram and TikTok . About Shapellx Shapellx is a full-category shapewear brand built on cutting-edge shaping technology and refined design aesthetics. Through premium international retailers such as Nordstrom and its own online platform, Shapellx connects with women who value both quality and style. The brand is dedicated to meeting the dual needs of fashion expression and body contouring in everyday wear, empowering women to radiate confidence from the inside out. Contact:Melina Schaefer [email protected] A video accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
